Company Overview

Biote Corp. (Nasdaq: BTMD) is a U.S.-based healthcare company focused on practitioner education, certification, and products supporting bioidentical hormone replacement therapy (BHRT). The company operates within the healthcare services and medical products industries, primarily serving physicians and medical practices that provide hormone optimization and wellness therapies. Biote’s core offering centers on a standardized, evidence-based approach to BHRT delivered through a network of trained clinicians.

The company generates revenue primarily through the sale of hormone therapy pellets, dietary supplements, and recurring education, training, and practice-support services for medical providers. Biote is positioned as a scalable platform that combines medical education, proprietary protocols, and product distribution. Founded in 2012, Biote expanded rapidly through clinician adoption and became a public company in 2022 following a merger with a special purpose acquisition company, marking its transition to a publicly traded healthcare services provider.

Business Operations

Biote operates through a single, integrated business model that supports medical practitioners offering BHRT. Its operations include clinician training and certification, ongoing educational programs, and the distribution of hormone pellets and related wellness products. Revenue is largely recurring and driven by practitioner utilization of Biote’s products and services within their patient practices.

The company’s operations are primarily domestic, with the majority of revenue generated in the United States. Biote controls proprietary treatment protocols, educational curricula, and a branded ecosystem designed to support physician adoption and patient retention. The business is conducted principally through its operating subsidiary Biote Medical, LLC, which manages practitioner relationships, logistics, and product fulfillment.

Strategic Position & Investments

Biote’s strategic direction emphasizes expanding its practitioner network, increasing utilization within existing clinics, and enhancing its educational and data-driven support tools. Growth initiatives focus on clinician recruitment, improved patient outcomes through protocol refinement, and cross-selling of supplements and ancillary wellness products within its network.

The company has pursued selective investments in technology, data analytics, and practice-management support to strengthen its platform rather than large-scale diversification. Public disclosures do not indicate material acquisitions beyond its core operating structure; where references to additional investments or acquisitions appear, data inconclusive based on available public sources.

Geographic Footprint

Biote is headquartered in Irving, Texas, and its operational footprint is concentrated in North America, with a predominant presence across the United States. Its clinician network spans numerous states, giving the company broad national reach within its core market.

While Biote has referenced interest from international practitioners, its revenue and operations remain primarily U.S.-focused. Any international activity is limited and not reported as a material contributor to consolidated financial results based on publicly available disclosures.

Leadership & Governance

Biote was founded by Gary S. Donovitz, who continues to shape the company’s strategic vision with an emphasis on physician-led care, standardization, and scalable healthcare delivery. Leadership philosophy centers on combining clinical education with operational consistency to support long-term practitioner partnerships.

Key executives include:

• Gary S. Donovitz – Founder & Chief Executive Officer
• Tracy Gapin, MD – Chief Medical Officer

The company is governed by a board of directors with experience across healthcare, finance, and public company oversight, aligning governance practices with its status as a Nasdaq-listed healthcare organization.